Page 172 - Genentech News Today

Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases and Immunology at the UMass Chan Medical... | April 24, 2023

Investegate announcements from UBTECH ROBOTICS CORP LTD, UBTECH Smart Elderly Care Solution honored as the winner of the 2023 Edison Awards™

According to a new market research report published by Future Market Insights, the global Primary Hyperoxaluria Treatment Market is expected to grow at a CAGR of 8.6% during the forecast period of 2023 to 2033. The market is expected to surpass US$ 41 million in value terms by the end of the aforementioned forecast...

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Safety concerns related to the widely used painkiller diclofenac may be tied to a little-studied drug-metabolizing enzyme whose expression can vary as much as 3,000 times from one individual to the next, according to new research. Findings from the study could be used to develop ways to identify individuals at risk of serious side effects from diclofenac and to determine safer dosing standards for specific populations, including women, young children and people of certain ethnicities. Used to co...

Brian M. Slomovitz, MD, discusses key efficacy and safety data seen with ribociclib and letrozole in the GOG 3026 trial and planned efforts to identify associated biomarkers and pursue FDA approval for the combination in advanced, recurrent low-grade serous ovarian cancer.

Healio Rheumatology | On May 23, 2022, U.S. Surgeon General Vivek Murthy, MD, issued an advisory on health worker burnout and wellbeing, declaring the situation a “crisis,” and addressing it a “top national priority.”Provider burnout — in rheumatology and other specialties — had been an ongoing issue dating back prior to the COVID-19 pandemic. However, the stresses of the pandemic

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

FORT MYERS, FLORIDA, USA, April 24, 2023 (GLOBE NEWSWIRE) -- FORT MYERS, FLORIDA, April 20, 2023-- UBTECH, a leading global AI and robotics company, was honored the Bronze award of the 2023 Edison Awards'

Philadelphia, PA (PRWEB) April 24, 2023 -- Gilbane Building Company, one of the world’s leading and longest-tenured, privately held and family-owned